Market Overview

Tenet Healthcare Said To Be Exploring Sale: How Far Is Management Willing To Go?

Tenet Healthcare Said To Be Exploring Sale: How Far Is Management Willing To Go?
Related THC
Montel Williams' Battle With Multiple Sclerosis And The Miracle Of Medical Marijuana
15 Biggest Mid-Day Gainers For Thursday
Saba Capital Management, L.P. Buys Clough Global Opportunities Fund, Morgan Stanley Emerging ... (GuruFocus)

Shares of Tenet Healthcare Corp (NYSE: THC) were trading higher by nearly 3 percent after Thursday's opening bell in reaction to reports that the company is exploring strategic alternatives, including a potential sale of itself.

However, investors holding on to Tenet's stock under the assumption the company will be bought out at a notable premium may need to reconsider, at least according to KeyBanc Capital Markets' Jason Gurda.

It is "unlikely" that Tenet Healthcare will sell itself given a high level of debt and lack of interest among potential strategic buyers, Gurda commented in a research report (see his track record here). At a $16 billion enterprise valuation, there are few companies that can even afford the price tag for a slow growth hospital company with possible exceptions being HCA Healthcare Inc (NYSE: HCA) and maybe Universal Health Services, Inc. (NYSE: UHS).

However, HCA's M&A activity has historically focused on expanding in specific geographic regions and buying Tenet Healthcare would result in a significant overlap in several markets, the analyst noted. Also, Universal Health Services may not have an appetite for new M&A deals after adding new debt to its balance sheet.

But what Tenet Healthcare could reasonably oversee to create value for investors is divesting individual hospitals and/or its Conifer subsidiary. Either action would be accretive to Tenet Healthcare's stock and accelerate de-leveraging.

However, it is unclear at this point "how far management is willing to go in breaking up the business."

Related Links:

Wall Street's M&A Chatter From September 13: Tenet, Potash, Oclaro, Lattice Semiconductor

5 Stocks To Watch For September 14, 2017

Latest Ratings for THC

Aug 2017Leerink SwannMaintainsOutperform
Aug 2017Deutsche BankMaintainsBuy
Aug 2017Credit SuisseMaintainsNeutral

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: Analyst Color News Health Care Rumors M&A Analyst Ratings Movers General Best of Benzinga


Related Articles (THC + HCA)

View Comments and Join the Discussion!